42 results on '"Cummings, James F."'
Search Results
2. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models
3. Evaluation of the certificate in emerging infectious disease research and the certificate in one health training programs, University of Florida
4. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults
5. Detection of qacA/B in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus from a Regional Healthcare Network in the Eastern United States
6. Randomized, Double-Blind, Phase 2a Trial of Faltiparum Malaria Vaccines RTS,S/AS01B and RTS.S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
7. Persistence of Vaccinia at the Site of Smallpox Vaccination
8. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research
9. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research
10. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya
11. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques
12. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A
13. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine
14. The RTS,S vaccine candidate for malaria
15. Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases
16. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research
17. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection
18. Visceral Leishmaniasis: Clinical Observations in 4 US Army Soldiers Deployed to Afghanistan or Iraq, 2002–2004
19. Vaccinia DNA in Blood After Smallpox Vaccination
20. Lack of vaccinia viremia after smallpox vaccination
21. New World monkey efficacy trials for malaria vaccine development: critical path or detour?
22. The View of a Public School From the Ivory Tower.
23. School Budgets and Economic Scarcity
24. The View of a Public School from the Ivory Tower
25. Use of Bibliometric Analysis to Assess the Scientific Productivity and Impact of the Global Emerging Infections Surveillance and Response System Program, 2006–2012
26. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy
27. Respiratory Infections in the U.S. Military: Recent Experience and Control
28. The State of Antimicrobial Resistance Surveillance in the Military Health System: A Review of Improvements Made in the Last 10 Years and Remaining Surveillance Gaps
29. Strengthening Malaria Prevention and Control: Integrating West African Militaries' Malaria Control Efforts. The Inaugural Meeting of the West African Malaria Task Force, April 24–26, 2013, Accra, Ghana
30. Evaluation of the certificate in emerging infectious disease research and the certificate in one health training programs, University of Florida
31. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
32. Plasmodium falciparum Infection during Suppressive Prophylaxis with Mefloquine Does Not Induce an Antibody Response to Merozoite Surface Protein-1(42)
33. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection
34. Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
35. Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
36. Common and Divergent Immune Response Signaling Pathways Discovered in Peripheral Blood Mononuclear Cell Gene Expression Patterns in Presymptomatic and Clinically Apparent Malaria
37. CHARACTERIZATION OF A HUMAN REFERENCE STANDARD FOR ANTIBODY TO PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 142
38. Detection of qacA/Bin Clinical Isolates of Methicillin-Resistant Staphylococcus aureusfrom a Regional Healthcare Network in the Eastern United States
39. Spending for Education — How Critical Have We Been?
40. School Budgets and Economic Scarcity
41. The Military and Its Potential Role in Malaria Elimination.
42. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.